论文部分内容阅读
目的:观察胃康I号方联合雷贝拉唑钠肠溶胶囊对中虚气逆型反流性食管炎(RE)患者的临床疗效.方法:采用随机数字表法将60例RE患者分为对照组和治疗组各30例,对照组予雷贝拉唑钠肠溶胶囊,每次20 mg,早晚各一次;治疗组在对照组基础上加用胃康I号方,每日1剂,疗程均为8周,分别观察两组疗效.结果:治疗组临床疗效、胃镜下炎症疗效均优于对照组,两组比较差异有统计学意义(P＜0.05);治疗组中医症候积分、GerdQ积分均明显低于对照组(P＜0.01);随访6个月治疗组复发率21.4％,明显低于对照组52.4％(P＜0.05).结论:胃康1号方联合雷贝拉唑钠肠溶胶囊治疗RE疗效好,能明显缓解临床症状,降低复发率.“,”Objective:To observe the clinical efficacy of Weikang Ⅰ formula combined rabeprazole sodium enteric-coated capsule on reflux esophagitis(RE) of middle deficiency and qi rebellion type. Method:Sixty patients with RE were randomly divided into the control group and the treatment group, 30 cases in each group by a random number table. Patients in both two groups were given rabeprazole sodium enteric-coated capsule 20 mg in the morning and evening, and patients in the treatment group was also given Weikang Ⅰformula, 1 dose Ya day. In the two groups, the treatment lasted for 8 weeks and the clinical efficacy was observed. Results:The clinical effect of syndromes and the effect on inflammation under gastroscopy in the treatment group were better than those in the control group, with statistical difference(P＜0.05). The treatment group was lower than the control group on the traditional Chinese medicine symptom score, GerdQ score, with significant difference(P＜0.01). At 6-month follow-up, the recurrence rate in the treatment group was 21.4％ and was significantly lower than that in the control group 52.4％(P＜0.05). Conclusion:Weikang Ⅰformula combined with rabeprazole sodium enteric-coated capsule showed better curative effect for RE. It could alleviate the clinical symptom and reduce the recurrence rate.